Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $81.60 Consensus PT from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $81.60.

A number of research analysts have recently weighed in on the company. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock valued at $5,205,798 over the last 90 days. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP boosted its holdings in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after buying an additional 30,331 shares in the last quarter. Element Squared LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $1,193,000. CWA Asset Management Group LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $907,000. Assenagon Asset Management S.A. purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $4,851,000. Finally, Tema Etfs LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $1,700,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $77.81 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a twelve month low of $55.64 and a twelve month high of $82.26. The company has a market cap of $9.23 billion, a PE ratio of 27.99, a P/E/G ratio of 0.32 and a beta of 0.84. The company’s 50 day moving average is $72.03 and its two-hundred day moving average is $70.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter last year, the company posted $1.11 earnings per share. The business’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts anticipate that Halozyme Therapeutics will post 7.54 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.